A Tale of 2 Biotechs With Competing Peanut Allergy Treatments

 One is Viaskin, created by DBV Technologies (NASDAQ: DBVT), which functions as an applied skin-patch that gradually increases the amount of tolerance for peanut protein in children with the allergy. The drug, however, is far from perfect and has to overcome severe hurdles before it has a shot at regulatory approval. Aimmune Therapeutics (NASDAQ: AIMT) is another biotech with an innovative treatment aimed at helping children with peanut allergy.